Follow-Up Efficacy Data of Imetelstat in Lower-Risk MDS

Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.

In an interview with Targeted Oncology, Amer Zeidan, MBBS, discussed the IMerge study and next steps for imetelstat for patients with lower-risk MDS.

In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.

Uwe Platzbecker, MD, discussed findings from recent phase 3 trials and their clinical implications for daily care in patients with lower-risk myelodysplastic neoplasms.

An analysis examined survival outcomes in several subgroups of patients with hematologic cancers compared with the overall population.

Results from the COMMANDS trial led the FDA to approve luspatercept for the treatment of anemia without prior erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.